Program Director Survey

Form Approve OMB No: xxxx-xxxx Exp. Date: xx-xx-xxxx

The public reporting burden of this information collection is estimated at 30 minutes, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor; a person is only required to respond to a collection of information if it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer, 1600 Clifton Road NW, MS D-74, Atlanta, GA 30333; Attn: PRA (xxxx-xxxx).

| Recipient organization name: | |
|------------------------------|--|
| Contact Person: | |

SECTION 1. STRATEGIC PLANNING AND PRIORITIZATION

- 1. What factors have impacted the development and/or enhancement of your State/Tribal Action Plan? (300 words)
- 2. How does your organization work in collaboration with partners and subrecipients to plan primary prevention activities in your state/territory/tribe? (750 characters)
- 3. What factors have facilitated effective collaboration with partners and subrecipients for program planning?
- 4. What barriers have you encountered with respect to collaborating with partners and subrecipients for program planning? How are you addressing those barriers?

SECTION 2. PARTNERSHIPS AND MEANINGFUL INVOLVEMENT

- 5. To what extent has your program made progress in participating in meaningful involvement with SA coalitions, Tribal SA coalitions, representatives from underserved communities of the State or Territory and other collaborators working to prevent SV?
 - Substantial progress
 - Moderate progress
 - O Very little progress

| | O No progress |
|--------|--|
| | O Not yet measured |
| 6. | Which partners have you identified as missing from your work to advance health equity? How will you communicate your shared goals and engage with these partners? |
| 7. | In what ways has your program collaborated with RPE-funded SA coalitions in your state/territory? |
| 8. | How, if at all, have you increased knowledge about SV prevention among your partners and subrecipients? |
| 9. | What lessons have you learned about collaboration and choosing partners and subrecipients strategically? |
| 10 | How do you share information and lessons learned on community and societal level prevention efforts with partners and subrecipients? |
| SECTIO | ON 3. CAPACITY BUILDING |
| | In what ways has your organization been able to assess your capacity to enhance and expand |
| | primary prevention and health equity work? |
| 12 | To what extent has your organization's capacity to facilitate, monitor, implement, and evaluate community and societal level SV prevention strategies and promote health equity increased since the start of the NOFO? O To a large extent O To a moderate extent O To a small extent |
| | O Not at all |
| 13 | . How has your organization been able to leverage findings from your primary prevention capacity assessment to enhance and expand primary prevention work? |
| 14 | How, if at all, have you increased capacity within your organization to facilitate, monitor, implement, and evaluate community and societal level SV prevention strategies and promote health equity? |
| 15 | How, if at all, have you increased capacity among partners and subrecipients to facilitate, monitor, implement, and evaluate community and societal level SV prevention strategies and promote health equity? |

- 16. What facilitators has your organization experienced with respect to increasing capacity for community and societal level SV prevention and promoting health equity?
- 17. What barriers is your program still experiencing with respect to increasing capacity for community and societal level SV prevention and promoting health equity? How are you addressing those challenges?

SECTION 4. IMPLEMENTATION

- 18. What factors have facilitated implementation of your SV prevention efforts since the start of the NOFO?
- 19. What legislative/political barriers, if any, have you encountered during the implementation of SV prevention efforts? What are you doing to address those barriers?
- 20. What additional barriers have you encountered during the implementation of SV prevention efforts? How are you addressing those barriers?
- 21. Can you describe any adaptations you made or are planning to make in order to make your programs accessible and available to participants regardless of age, race/ethnicity, sexual orientation, gender identity, sex, ability, or socioeconomic status?
- 22. What have been effective ways to engage partners and subrecipients to implement prevention strategies?
- 23. What have been barriers to engaging partners and subrecipients to implement prevention strategies? How are you addressing those barriers?
- 24. What changes, if any, have you observed in partners' and subrecipients' knowledge and attitudes toward community and societal level SV prevention and health equity promotion?
- 25. Regarding the observed changes, how do these align with your goals for community and societal level SV prevention and health equity?

SECTION 5. PROGRESS TOWARD GOALS

26. Think about the progress your program has made toward intended program outcomes for SV prevention and health equity promotion. Can you share any success stories that reflect the efforts you have made toward achieving program outcomes? (3,000 characters)

SECTION 6. REACH

| 27. To date, what progress have you made reaching your priority population(s) with SV prevention efforts? |
|---|
| O Substantial progress |
| O Moderate progress |
| O Very little progress |
| O No progress |
| O Not yet measured |
| 28. What methods are you using to engage your priority population(s) as you implement and monitor progress on your SV prevention efforts? |
| 29. Please describe what factors have impacted the current progress you have made to reach your priority population(s). |
| 30. Are you currently reaching or planning to reach other populations? If so, which populations and how do you intend to reach those additional populations? |
| SECTION 7. SUSTAINABILITY |
| 31. How are you working to ensure the sustainability of your activities and partnerships? |
| SECTION 8. HEALTH EQUITY |
| 32. How is your program implementing SV prevention strategies to increase health equity? |
| 33. What challenges have you faced with incorporating health equity into SV prevention efforts? |
| 34. How have you, or how do you plan to, overcome these challenges? |
| 35. How, if at all, could CDC support you in overcoming these challenges? |
| 36. How have you, or how do you plan to, involve and incorporate community feedback in refining and adapting your SV prevention strategies to better align with health equity goals? |
| 37. What lessons learned about addressing health inequities would you share with other programs? |
| SECTION 9. DATA TO ACTION |
| 38. To what extent do you feel your organization has adequate access to data needed for planning, monitoring, and evaluation of community and societal level SV prevention activities? O To a very large extent O To a large extent |

| O | To some extent |
|--------------------------|--|
| 0 | To little extent |
| О | To no extent |
| group activ O O | hat extent does your organization use data (e.g., surveys, interviews, reports, focus os) for planning, monitoring, and evaluation of community and societal level SV prevention ities? To a very large extent To a large extent To some extent To little extent |
| 0 | To no extent |
| 40. How | are state and local data being used to inform program strategies and activities? |
| 41. How | is your organization increasing data access and sharing among partners and subrecipients? |
| | t factors have facilitated enhancing data sharing and use among partners and ecipients? |
| 43. Wha | t barriers have been encountered with enhancing data sharing and use among partners |

SECTION 10. TECHNICAL ASSISTANCE

44. What types of technical assistance and support from CDC and its technical assistance partners have been most useful to your organization?

and subrecipients? How are you addressing those barriers?

45. How could technical assistance and support CDC and its technical assistance partners provide be improved?

SECTION 11. CONCLUSION

46. Thank you for taking the time to complete this survey! We value your time and really appreciate your input. If you have any additional comments about your program's implementation, please provide them here.